medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-3-44-46medsovet-1748Research ArticleОСЛОЖНЕНИЯ САХАРНОГО ДИАБЕТАCOMPLICATIONS OF DIABETESРОЛЬ ДИСЛИПИДЕМИИ В ПРОГРЕССИРОВАНИИ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИTHE ROLE OF DYSLIPIDEMIA IN THE PROGRESSION OF DIABETIC RETINOPATHYКузьминА. Г.KuzminA. G.

к.м.н.,

Москва

PhD in Medicine, 

Moscow

МартыновС. А.MartynovS. A.

к.м.н., 

Москва

PhD in Medicine, 

Moscow

ШестаковаМ. В.ShestakovaM. V.

д.м.н., профессор, академик РАН, 

Москва

MD, Prof., academician of the RAS,

Moscow

Эндокринологический научный центрРоссияEndocrinological Scientific CentreRussian Federation201730122017034446Copyright © Кузьмин А.Г., Мартынов С.А., Шестакова М.В., 20172017Кузьмин А.Г., Мартынов С.А., Шестакова М.В.Kuzmin A.G., Martynov S.A., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1748

Ведущую роль в образовании новых сосудов сетчатки из эндотелиальных клеток, повышении сосудистой проницаемости с формированием экссудаций и отека макулы, приводящим к развитию необратимых осложнений и потере зрения, играют факторы ангиогенеза, роста (сосудистый эндотелиальный фактор роста (VEGF), ангиопоэтин-2, инсулин-подобный фактор роста и др.) и цитокины. Хотя крупные клинические исследования выявили, что жесткий контроль гликемии и нормализация системного артериального давления снижают риск развития и прогрессирования диабетической ретинопатии (ДР), взаимосвязь липидных нарушений и повреждения сетчатки остается не до конца изученной.

Angiogenesis factors, growth factors (vascular endothelial growth factor (VEGF), angiopoietin-2, insulin-like growth factor, etc.) and cytokines play the leading role in the production by endothelial cells of new retinal blood vessels, increased vascular permeability resulting in exudation and macular edema leading to the development of irreversible complications and vision loss. Although large-scale clinical trials demonstrated that tight control of glycemia and normalization of systemic blood pressure reduce the risk of progression of diabetic retinopathy (DR), the relationship between lipid disorders and retinal damage is not fully understood.

сахарный диабетдислипидемиядиабетическая ретинопатияdiabetes mellitusdyslipidemiadiabetic retinopathyReferencesKlein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology, 1991, 98(8): 1261–1265.Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology, 1991, 98(8): 1261–1265.Chew E.Y., Klein M.L., Ferris F.L. et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol, 1996, 114(9): 1079–1084.Chew E.Y., Klein M.L., Ferris F.L. et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol, 1996, 114(9): 1079–1084.Miljanovic B, Glynn RJ, Nathan DM et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes, 2004, 53(11): 2883–2892.Miljanovic B, Glynn RJ, Nathan DM et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes, 2004, 53(11): 2883–2892.Rema M, Srivastava BK, Anitha B at al. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med, 2006, 23(9): 1029–1036.Rema M, Srivastava BK, Anitha B at al. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med, 2006, 23(9): 1029–1036.Smolders B, Lemmers R, Thijs V. Lipoprotein(a) and stroke: a meta-analysis of observational studies. Stroke, 2007, 38(6): 1959–1966.Smolders B, Lemmers R, Thijs V. Lipoprotein(a) and stroke: a meta-analysis of observational studies. Stroke, 2007, 38(6): 1959–1966.Stitt AW, Frizzell N, Thorpe SR. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des, 2004, 10(27): 3349-3360.Stitt AW, Frizzell N, Thorpe SR. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des, 2004, 10(27): 3349-3360.Gordon B, Chang S, Kavanagh M et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol, 1991, 112(4): 385–391.Gordon B, Chang S, Kavanagh M et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol, 1991, 112(4): 385–391.Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract, 2002, 56(1): 1–11.Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract, 2002, 56(1): 1–11.Wassmann S, Laufs U, Muller K et al. Сellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002, 22: 300–305.Wassmann S, Laufs U, Muller K et al. Сellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002, 22: 300–305.Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364(9435): 685–696.Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364(9435): 685–696.Zhang J, McGwin GJ. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol, 2007 Aug, 125(8): 1096-1099.Zhang J, McGwin GJ. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol, 2007 Aug, 125(8): 1096-1099.Harrold BP, Marmion VJ, Gough KR. A doubleblind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes, 1969, 18(5): 285–291.Harrold BP, Marmion VJ, Gough KR. A doubleblind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes, 1969, 18(5): 285–291.Duncan LJ, Cullen JF, Ireland JT et al. A threeyear trial of atromid therapy in exudative diabetic retinopathy. Diabetes, 1968, 17(7): 458–467.Duncan LJ, Cullen JF, Ireland JT et al. A threeyear trial of atromid therapy in exudative diabetic retinopathy. Diabetes, 1968, 17(7): 458–467.Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK, 1994, 94(2): 554–562.Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK, 1994, 94(2): 554–562.Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet, 2007, 370(9600): 1687–1697.Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet, 2007, 370(9600): 1687–1697.Panigrahy D, Kaipainen A, Huang S et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A, 2008, 105: 985–990.Panigrahy D, Kaipainen A, Huang S et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A, 2008, 105: 985–990.Meissner M, Stein M, Urbich C et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1- dependent DNA binding and transactivation. Circ Res, 2004, 94: 324–332.Meissner M, Stein M, Urbich C et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1- dependent DNA binding and transactivation. Circ Res, 2004, 94: 324–332.Tomizawa A, Hattori Y, Inoue T et al. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism, 2011, 60: 513–522.Tomizawa A, Hattori Y, Inoue T et al. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism, 2011, 60: 513–522.Marx N, Sukhova GK, Collins T et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99: 3125–3131.Marx N, Sukhova GK, Collins T et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99: 3125–3131.Ibarra-Lara L, Hong E, Soria-Castro E et al. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. J Cardiovasc Pharmacol, 2012, 60: 323–334.Ibarra-Lara L, Hong E, Soria-Castro E et al. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. J Cardiovasc Pharmacol, 2012, 60: 323–334.Chew EY, Ambrosius WT, Davis MD et al. ACCORD Study Group. ACCORD Eye Study GroupEffects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363: 233–244.Chew EY, Ambrosius WT, Davis MD et al. ACCORD Study Group. ACCORD Eye Study GroupEffects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363: 233–244.Morton J, Zoungas S, Li Q et al. ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care, 2012, 35(11): 2201–2206.Morton J, Zoungas S, Li Q et al. ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care, 2012, 35(11): 2201–2206.Ibrahim AS, Tawfik AM, Hussein KA et al. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids. Biochim Biophys Acta, 2015, 1851(3): 290-298.Ibrahim AS, Tawfik AM, Hussein KA et al. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids. Biochim Biophys Acta, 2015, 1851(3): 290-298.Ibrahim AS, Elshafey S, Sellak H et al. A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res, 2015, 56(3): 599-611.Ibrahim AS, Elshafey S, Sellak H et al. A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res, 2015, 56(3): 599-611.SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res, 2005, 24(1): 87-138.SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res, 2005, 24(1): 87-138.

The authors declare that there are no conflicts of interest present.